NCT06520540

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.

Conditions

• Glucagon-Like Peptide-1 Receptor Agonists

Interventions

Type	Name	Description
DRUG	HDM1002 100 mg QD 12weeks	Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
DRUG	HDM1002 200 mg QD 12weeks	Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
DRUG	HDM1002 400 mg QD 12weeks，Q 2W for titration	Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
DRUG	HDM1002 400 mg QD 12weeks，Q 3W for titration	Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
DEVICE	Placebo	Placebo

Timeline

• Start date: 2024-07-28
• Primary completion: 2024-11-30
• Completion: 2024-12-30
• First posted: 2024-07-25
• Last updated: 2024-07-25

Locations

1 site across 1 country: China